Organization | Walvax Biotechnology Co., Ltd.

Walvax Biotechnology Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Kunming China (2001)

Status: No NME R&D (2001)

Organization Overview

First Clinical Trial

2012

NCT02285036

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Walvax Biotechnology Co., Ltd. | Yuxi Walvax Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

menacwy conjugate vaccine (2 trials)

Drugs in Phase 3 Trials (6)

Key: Walvax Biotechnology Co., Ltd. (4) Acquired (2)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

hpv 16/18 vaccine (Cervarix) (4 trials)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (2 trials)

multi-valent pneumococcal conjugate vaccine (1 trial)

pneumococcal 7-valent conjugate vaccine (prevnar) (1 trial)

sars-cov-2 mrna vaccine (1 trial)

Drugs in Phase 2 Trials (4)

Key: Walvax Biotechnology Co., Ltd. (0) Acquired (4)

202-cov (3 trials)

aluminum hydroxide (Gaviscon) (2 trials)

bnt162b2 (3 trials)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

Drugs in Phase 1 Trials (1)

rq3013 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 4)

Pneumococcal Infections (Phase 3)

Pneumonia (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 17
# of Trial APIs: 12